Fig. 3.

Association of early IFN therapy with early recovery from COVID-19 required early GC administration. a, b Cumulative incidence curves for hospital discharge among survivors with early (a) or late GC administration (b). n = 83 (early IFN) and 34 (no early IFN) for a, 33 (early IFN) and 50 (no early IFN) for b. c, d Cumulative incidence curves for symptom relief among survivors with early (c) or late GC administration (d). n = 83 (early IFN) and 34 (no early IFN) for c, 33 (early IFN) and 50 (no early IFN) for d. e, f Bar graph of PVS prevalence among patients ceased viral shedding before discharge and with early (e) or late GC administration (f). n = 83 (early IFN) and 38 (no early IFN) for e, 33 (early IFN) and 50 (no early IFN) for f